Exploring Compound Promiscuity Patterns and Multi-Target Activity Spaces

Compound promiscuity is rationalized as the specific interaction of a small molecule with multiple biological targets (as opposed to non-specific binding events) and represents the molecular basis of polypharmacology, an emerging theme in drug discovery and chemical biology. This concise review focuses on recent studies that have provided a detailed picture of the degree of promiscuity among different categories of small molecules. In addition, an exemplary computational approach is discussed that is designed to navigate multi-target activity spaces populated with various compounds.

• Publication year

  2014

• Venue

  Computational and Structural Biotechnology Journal

• Publication date

  2014-01-29

• Fields of study

  Medicine, Chemistry, Computer Science

• Identifiers
  DOI 10.5936/csbj.201401003PMID 24688751PMCID 3962225
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Perspective on Computational Chemogenomics

  2013cited by this paper
• Compound promiscuity: what can we learn from current data?

  2013cited by this paper
• What is the Likelihood of an Active Compound to Be Promiscuous? Systematic Assessment of Compound Promiscuity on the Basis of PubChem Confirmatory Bioassay Data

  2013cited by this paper
• On the origins of drug polypharmacology

  2013cited by this paper
• High-resolution view of compound promiscuity

  2013cited by this paper
• Systematic mining of analog series with related core structures in multi-target activity space

  2013cited by this paper
• Promiscuity profiles of bioactive compounds: potency range and difference distributions and the relation to target numbers and families

  2013cited by this paper
• High-resolution view of compound promiscuity.

  2013cited by this paper
• MMP-Cliffs: Systematic Identification of Activity Cliffs on the Basis of Matched Molecular Pairs

  2012cited by this paper
• SAR Matrices: Automated Extraction of Information-Rich SAR Tables from Large Compound Data Sets

  2012cited by this paper
• Large Scale Prediction and Testing of Drug Activity on Side-Effect Targets

  2012cited by this paper
• Growth of Ligand-Target Interaction Data in ChEMBL Is Associated with Increasing and Activity Measurement-Dependent Compound Promiscuity

  2012cited by this paper
• Structural Insights into the Molecular Basis of the Ligand Promiscuity

  2012cited by this paper
• Matched molecular pair analysis of small molecule microarray data identifies promiscuity cliffs and reveals molecular origins of extreme compound promiscuity.

  2012cited by this paper
• ChEMBL: a large-scale bioactivity database for drug discovery

  2011cited by this paper
• PubChem's BioAssay Database

  2011cited by this paper
• DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs

  2010cited by this paper
• Small molecules of different origins have distinct distributions of structural complexity that correlate with protein-binding profiles

  2010cited by this paper
• Drug profiling: knowing where it hits.

  2010cited by this paper
• Computationally Efficient Algorithm to Identify Matched Molecular Pairs (MMPs) in Large Data Sets

  2010cited by this paper
• Systems approaches to polypharmacology and drug discovery.

  2010cited by this paper
• Targeting the cancer kinome through polypharmacology

  2010cited by this paper
• Predicting new molecular targets for known drugs

  2009cited by this paper
• A chemogenomic approach to drug discovery: focus on cardiovascular diseases.

  2009cited by this paper
• Drug Target Identification Using Side-Effect Similarity

  2008cited by this paper
• Data completeness—the Achilles heel of drug-target networks

  2008cited by this paper
• Drug—target network

  2007cited by this paper
• New uses for old drugs

  2007cited by this paper
• Global mapping of pharmacological space

  2006cited by this paper
• Drug repositioning: identifying and developing new uses for existing drugs

  2004cited by this paper

• From library to landscape: integrative annotation workflows for compound libraries in drug repurposing

  2025influential citation
• Anticancer drug development against ribosome synthesis and the nucleolus

  2025cites this paper
• Time‐evolved metrics for safety pharmacological assessments of small molecules and biologics

  2025cites this paper
• Non-oncology orphan drug development: Productivity and probability of success.

  2025cites this paper
• A Comprehensive Review of Antimicrobial Agents Against Clinically Important Bacterial Pathogens: Prospects for Phytochemicals

  2024cites this paper
• Multi-level advances in databases related to systems pharmacology in traditional Chinese medicine: a 60-year review

  2023influential citation
• Analgesic Activity of 5-Acetamido-2-Hydroxy Benzoic Acid Derivatives and an In-Vivo and In-Silico Analysis of Their Target Interactions

  2023cites this paper
• Multitargeting: An Alternative Approach to Tackling Multidrug Resistance Issues in Tuberculosis.

  2023cites this paper
• The Transporter-Mediated Cellular Uptake and Efflux of Pharmaceutical Drugs and Biotechnology Products: How and Why Phospholipid Bilayer Transport Is Negligible in Real Biomembranes

  2021cites this paper
• Cheminformatics analysis of molecular datasets of transcription factors associated with quorum sensing in Pseudomonas aeruginosa

  2021cites this paper
• Target identification and polypharmacology of nutraceuticals

  2021cites this paper
• Toward an Understanding of Pan-Assay Interference Compounds and Promiscuity: A Structural Perspective on Binding Modes

  2021cites this paper
• Chemical activation of Arabidopsis SnRK2.6 by pladienolide B

  2021cites this paper
• A Definition of “Multitargeticity”: Identifying Potential Multitarget and Selective Ligands Through a Vector Analysis

  2020cites this paper
• Selective toxicity of antibacterial agents—still a valid concept or do we miss chances and ignore risks?

  2020cites this paper
• Repositioned Drugs for Chagas Disease Unveiled via Structure-Based Drug Repositioning

  2020cites this paper
• Melatonin controversies, an update

  2020cites this paper
• VAE-Sim: A Novel Molecular Similarity Measure Based on a Variational Autoencoder

  2020cites this paper
• Deep Ranking Analysis by Power Eigenvectors (DRAPE): A polypharmacology case study

  2020cites this paper
• Unraveling Plant Natural Chemical Diversity for Drug Discovery Purposes

  2020cites this paper
• Virtual screening web servers: designing chemical probes and drug candidates in the cyberspace

  2020cites this paper
• Natural Product Target Network Reveals Potential for Cancer Combination Therapies

  2019cites this paper
• Perspective on Antibacterial Lead Identification Challenges and the Role of Hypothesis-Driven Strategies

  2019cites this paper
• In Silico Drug-Target Profiling.

  2019cites this paper
• In Silico Modeling of FDA-Approved Drugs for Discovery of Therapies Against Neglected Diseases: A Drug Repurposing Approach

  2019cites this paper
• Dealing with frequent hitters in drug discovery: a multidisciplinary view on the issue of filtering compounds on biological screenings

  2019cites this paper
• Organic Isothiocyanates as Hydrogen Sulfide Donors

  2019cites this paper
• Structure-Activity Relationships in Metal-Binding Pharmacophores for Influenza Endonuclease.

  2018cites this paper
• Re-emergence of an orphan therapeutic target for the treatment of resistant prostate cancer – a thorough conformational and binding analysis for ROR-γ protein

  2018cites this paper
• Natural Product Target Network in Cancer : Definition and Application

  2018cites this paper
• Feature optimization in high dimensional chemical space: statistical and data mining solutions

  2018cites this paper
• How to Achieve Better Results Using PASS-Based Virtual Screening: Case Study for Kinase Inhibitors

  2018cites this paper
• THE PURDUE UNIVERSITY GRADUATE SCHOOL STATEMENT OF COMMITTEE APPROVAL

  2018cites this paper
• Enhancing Molecular Promiscuity Evaluation Through Assay Profiles

  2018cites this paper
• Inhibitors and chemical probes for molecular chaperone networks

  2018cites this paper
• Network‐based Approaches in Pharmacology

  2017cites this paper
• A simple mathematical approach to the analysis of polypharmacology and polyspecificity data

  2017cites this paper
• Differential Compound Prioritization via Bi-Directional Selectivity Push with Power

  2017cites this paper
• Computational approaches for innovative antiepileptic drug discovery

  2016cites this paper
• Network Pharmacology and Epilepsy

  2016cites this paper
• Is imatinib a prototypical example of targeted drug therapy?

  2016cites this paper
• Tutorial #2

  2016cites this paper
• Molecular Mechanism of Action of Antimalarial Benzoisothiazolones: Species-Selective Inhibitors of the Plasmodium spp. MEP Pathway enzyme, IspD

  2016cites this paper
• User instructions and tutorials of the synergyfinder package

  2016cites this paper
• Physicochemical characteristics of structurally determined metabolite-protein and drug-protein binding events with respect to binding specificity

  2015cites this paper
• Synthetic biology for pharmaceutical drug discovery

  2015cites this paper
• Multiple binding sites in the nicotinic acetylcholine receptors: An opportunity for polypharmacolgy.

  2015cites this paper
• Strong Nonadditivity as a Key Structure–Activity Relationship Feature: Distinguishing Structural Changes from Assay Artifacts

  2015cites this paper
• Introduction to Molecular Similarity and Chemical Space

  2014cites this paper